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12-0-tetradecanoylphorbol-13-acetate (TPA) stimulates protein kinase C (PKC) which mediates apoptosis in androgen-sensitive
LNCaP human prostate cancer cells. The downstream signals of PKC that mediate TPA-induced apoptosis in LNCaP cells are unclear.
In this study, we found that TPA activates the c-Jun NH2-terminal kinase (JNK)/c-Jun/AP-1 pathway. To explore the possible role that
the JNK/c-Jun/AP-1 signal pathway has on TPA-induced apoptosis in LNCaP cells, we stably transfected the scaffold protein, JNK
interacting protein 1 (JIP-1), which binds to JNK inhibiting its ability to phosphorylate c-Jun. TPA (10
 9–10
 7moll
 1) caused
phosphorylation of JNK in both wild-type and JIP-1-transfected (LNCaP-JIP-1) cells. It resulted in phosphorylation and upregulation of
expression of c-Jun protein in the wild-type LNCaP cells, but not in the JIP-1-transfected LNCaP cells. In addition, upregulation of AP-
1 reporter activity by TPA (10
 9moll
 1) occurred in LNCaP cells but was abrogated in LNCaP-JIP-1 cells. Thus, TPA stimulated c-
Jun through JNK, and JIP-1 effectively blocked JNK. TPA (10
 12–10
 8moll
 1) treatment of LNCaP cells caused their growth
inhibition, cell cycle arrest, upregulation of p53 and p21
waf1, and induction of apoptosis. All of these effects were significantly
attenuated when LNCaP-JIP-1 cells were similarly treated with TPA. A previous study showed that c-Jun/AP-1 blocked androgen
receptor (AR) signaling by inhibiting AR binding to AR response elements (AREs) of target genes including prostate-specific antigen
(PSA). Therefore, we hypothesised that TPA would not be able to disrupt the AR signal pathway in LNCaP-JIP-1 cells. Contrary to
expectation, TPA (10
 9–10
 8moll
 1) inhibited DHT-induced AREs reporter activity and decreased levels of PSA in the LNCaP-JIP-
1 cells. Taken together, TPA, probably by stimulation of PKC, phosphorylates JNK, which phosphorylates and increases expression of
c-Jun leading to AP-1 activity. Growth control of prostate cancer cells can be mediated through the JNK/c-Jun pathway, but androgen
responsiveness of these cells can be independent of this pathway, suggesting that androgen independence in progressive prostate
cancer may not occur through activation of this pathway.
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12-0-tetradecanoylphorbol-13-acetate (TPA) exerts a variety of
effects on cells that include proliferation, malignant transforma-
tion, differentiation, and cell death (Hunter and Karin, 1992).
Growth stimulation induced by TPA was shown in fibroblasts,
epidermal cells, lymphocytes, and several type of cancer cells
including KG-1, a very immature human myeloblastic leukaemia
cell line (Koeffler, 1981; Agadir et al, 1999); in contrast, TPA
induced differentiation and growth arrest of human U937
myelomonocytic and HL-60 myeloblastic leukaemia cells (Rovera
et al, 1979; Koeffler et al, 1981; Gaynor et al, 1991; Kaneki et al,
1999; Takada et al, 1999). Previous studies suggested that
upregulation of c-Jun (Gaynor et al, 1991), tumour necrosis factor
a (TNF a) (Takada et al, 1999), or protein kinase C (PKC) b
(Kaneki et al, 1999) might play an important role in the induction
of differentiation and cell growth arrest in these cells. In addition,
TPA was shown to induce apoptosis in LNCaP, an androgen-
sensitive human prostate cancer cell line through the upregulation
of PKC-d (Fujii et al, 2000), -a (Garzotto et al, 1998), or ceramide
synthesis (Powell et al, 1996). Other studies also showed that TPA
upregulated the expression of p21
waf1 and downregulated the levels
of c-Myc as growth of LNCaP cells slowed (Mitchell and El-Deiry,
1999).
Through the PKC pathway, TPA phosphorylates c-Jun-NH2-
terminal protein kinase (JNK), which belongs to the mitogen-
activated protein kinase (MAPK) family (Karin, 1995). Phosphory-
lated JNK rapidly phosphorylates Ser-63 and Ser-73 of the c-Jun
amino terminus, resulting in induction of c-Jun synthesis. The
activity of c-Jun/AP-1 is regulated by increased synthesis and
phosphorylation of c-Jun (Karin, 1995; Davis, 2000). c-Jun-NH2-
terminal protein kinase has been suggested to enhance the
induction of apoptosis; however, the mechanism by which this
occurs is unclear. One possibility is that phosphorylated c-Jun
causes the release of cytochrome c from mitochondria which then
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sacts with Apaf-1 to activate caspase-9 and caspase-3, and
orchestrates apoptosis (Behrens et al, 1999; Davis, 2000). 12-0-
tetradecanoylphorbol-13-acetate has been shown to enhance AP-1
transcriptional activity in LNCaP cells (Sato et al, 1997); but the
contribution of the JNK/c-Jun/AP-1 pathway to TPA-induced
apoptosis in LNCaP cells remains to be fully elucidated.
PSA belongs to the kallikrein-like serine protease family. It is
produced almost exclusively by the prostate epithelial cells, and is
used as a serum marker for diagnosis and progression of prostate
cancer (Polascik et al, 1999). The 50 upstream promoter and
enhancer region of the PSA gene contains several androgen
receptor response elements (AREs) to which ligand-activated
androgen receptor (AR) binds and induces expression of PSA
(Huang et al, 1999; Hisatake et al, 2000). Previous studies showed
that TPA downregulated the expression of PSA without any
downregulation of levels of AR in LNCaP cells (Andrews et al,
1992; Sato et al, 1997). The investigators suggested that c-Jun/AP-1
played an integral role by binding to the DNA-binding domain of
AR, disrupting the AR/ARE complex formation (Sato et al, 1997).
Recently, two cytoplasmic proteins identified as JNK interacting
proteins 1 and 2 (JIP-1/2), were found to bind selectively to JNK
but not to other group of MAPKs families including p38 and
extracellular signal-regulated protein kinase (ERK) (Dickens et al,
1997; Whitmarsh et al, 1998; Yasuda et al, 1999; Harding et al,
2001). Overexpression of JIP-1 caused the cytoplasmic retention of
JNK and thereby inhibited the expression of genes mediated by
JNK, including c-Jun (Dickens et al, 1997; Whitmarsh et al, 1998;
Yasuda et al, 1999; Harding et al, 2001). Moreover, recent studies
showed that JIP-1 inhibited the biological actions of the JNK signal
pathway. Overexpression of JNK-binding domain (JBD) of JIP-1
suppressed the malignant transformation of murine B cells
expressing Bcr/Abl, an oncogene which activates the JNK signal
pathway (Dickens et al, 1997). Also, overexpression of JBD of JIP-1
prevented apoptosis of neurons after withdrawal of nerve growth
factor (Harding et al, 2001).
In this study, we explore the role of the JNK/c-Jun/AP-1 signal
pathway in TPA-induced apoptosis and downregulation of PSA in
LNCaP cells by stably transfecting JBD of JIP-1 in these cells and
studying their biological responses compared to wild-type cells.
MATERIALS AND METHODS
Cell culture
LNCaP cells were obtained from American Type Culture Collection
(Rockville, MD, USA) and maintained in RPMI 1640 with 10% FCS.
Chemicals
TPA and JNK inhibitor SP600125 were obtained from Sigma (St
Louis, MO, USA) and Calbiochem (San Diego, CA, USA),
respectively.
Soft agar colony assay
Cells were cultured in a two-layer soft agar system for 14 days as
previously described (Hisatake et al, 1999). Washed, single-cell
suspension of cells were enumerated and plated into 24-well flat-
bottom plates with a total of 1 10
3 cellswell
 1 in a volume of
400mlwell
 1. The feeder layer was prepared with agar that had
been equilibrated at 421C. Prior to this step, TPA was pipetted into
the wells. After incubation, colonies were counted. Experiments
were carried out twice using triplicate plates.
MTT assay
Cells (10
4ml
 1) were incubated with various concentrations of
TPA (10
 10–10
 8moll
 1) for 4 days in 96-well plates (Flow
Laboratories, Irvine, CA, USA). After culture, cell number and
viability were evaluated by measuring the mitochondrial-depen-
dent conversion of the tetrazolium salt, MTT (Sigma), to a colored
formazan product. MTT (0.5mgml
 1 in PBS) was added to each
well and incubated for 4h at 371C. The medium was then carefully
aspirated, and dimethyl sulfoxide (DMSO; Burdick & Jackson,
Muskegon, MI, USA) was added to solubilise the coloured
formazan product. Absorbance was read at 540nm on a scanning
multiwell spectrophotometer (Bio-Rad) after agitating the plates
for 5min on a shaker.
Cell cycle analysis
Cells were incubated for 24h either with or without TPA (10
 9–
10
 8moll
 1). They were fixed in chilled methanol overnight before
staining with 50mlml
 1 propidium iodide (PI) in the presence of
RNase (Promega, Madison, WI, USA), as described previously
(Hisatake et al, 1999). Cell cycle status was analysed on FACscan
Flow Cytometery and CellFit Cell-Cycle Analysis software.
Assessment of apoptosis
Apoptotic cell death was examined by terminal deoxyribonucleo-
tide transferase-mediated dUTP nick-end labeling (TUNEL)
method using the In situ Cell Death Detection kit (Roche
Molecular Biochemicals, Germany), according to the manufac-
ture’s instruction. For quantification, three different fields were
counted under the microscope and at least 300 cells were counted
in each field. All experiments were performed twice.
Plasmids
ARE4-E4 Lux, which is the multimerised four consensus AREs
from the PSA promoter cloned upstream of the luciferase gene in
the pGL3 vector (Promega, Chicago, IL), was used (Huang et al,
1999; Hisatake et al, 2000). TRE-Luc construct was a generous gift
from Christopher K Glass (University of California, San Diego, CA,
USA) (Ricote et al, 1998). The FLAG-tagged JNK-binding domain
(JBD) of JIP-1 (residues 127–281) was cloned into a pcDNA3
vector (Clontech, San Francisco, CA, USA) and was a generous gift
from Charles L Sawyers (University of California, Los Angeles)
(Dickens et al, 1997).
Establishment of stable transfected LNCaP cell line
LNCaP cells were transfected with the JBD-pcDNA3 vector using
GenePORTER transfection reagent (Gene Therapy Systems, Inc.,
San Diego, CA, USA). Selection was performed with 800mgml
 1
G418 (Omega Scientific, Inc., Tarzana, CA, USA). The expression
of JIP-1 was confirmed by Western blot analysis using anti-Flag
antibody (Sigma).
Transfections and luciferase assay
LNCaP or LNCaP-JIP-1 cells were plated in 24-well plates and
incubated until 60–80% confluency. Cells were transfected with
the indicated plasmids using the GenePORTER transfection.
Following transfection, cells were incubated with 10% charcoal-
stripped FBS RPMI 1640 either with or without DHT (10
 8moll
 1)
and either with or without TPA for various durations. Luciferase
activity in cell lysates was measured by Dual Luciferase assay
system (Promega, Madison, WI, USA). Luciferase activity was
normalised by renilla activity. The results were presented as the
fold induction, which is the relative luciferase activity of the
treated cells over that of control cells. All transfection experiments
were carried out in triplicate wells and repeated separately at least
three times.
JIP-1 protects LNCaP cells from cell growth arrest and apoptosis
T Ikezoe et al
2018
British Journal of Cancer (2004) 90(10), 2017–2024 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sWestern blot analyses
Cells were seeded on 60mm plates and incubated until 60–80%
confluency, then the medium was replaced with RPMI 1640
containing 10% charcoal-striped FBS either with or without DHT
(10
 8moll
 1) and either with or without TPA. After incubation,
cells were washed twice in PBS, and whole-cell lysates were
prepared; cells were suspended in lysis buffer (50mM Tris (pH 8.0),
150mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP 40,
100mgml
 1 phenylmethysulphonyl fluoride, 1mM NaF, 1mM
NaVO3,2 mgml
 1 aprotinin, 1mgml
 1 pepstatin, and 10mgml
 1
leupeptin), and placed on ice for 30min. After centrifugation at
15000g for 20min at 41C, the supernatant was collected. Protein
concentrations were quantitated using a Bio-Rad assay (Bio-Rad
Laboratories, Hercules, CA, USA). Proteins were resolved on a 4–
15% SDS polyacrylamide gel, transferred to an immobilon
polyvinylidene difuride membrane (Amersham Corp., Arlington
Heights, IL, USA), and probed sequentially with a variety of
antibodies. Anti-c-Jun (sc-44, Santa Cruz, Santa Cruz, CA, USA),
anti-p-c-Jun (KM-1, Santa Cruz), anti-JNK (sc-571, Santa Cruz),
anti-p-JNK (sc-6254, Santa Cruz), anti-PSA C-19 (Santa Cruz), p-
53 (Santa Cruz), p21
waf1 (Calbiochem, Darmstadt, Germany), and
anti-actin antibody (Santa Cruz) were used. The blots were
developed using the enhanced chemiluminescence kit (Amersham
Corp.).
Evaluation of DNA-binding activity of AP-1 by enzyme-
linked immunosorbent assay (ELISA)
The DNA-binding activity of AP-1 was quantified by ELISA using
the Trans-AM AP-1 Transcription Factor Assay kit (Active Motif
North America, Carlsbad, CA, USA), according to the instructions
of the manufacturer. Briefly, nuclear extracts were prepared as
previously described and incubated in 96-well plates coated with
immobilised oligonucleotide (50-CGCTTGATGAGTCAGCCGGAA-
30) containing a consensus (50-TGAGTCA-30)-binding site for AP-
1. AP-1 binding to the target oligonucleotide was detected by
incubation with primary antibody specific for the activated form of
c-Jun (Active Motif North America), visualised by anti-IgG
horseradish peroxidase conjugate and Developing Solution, and
quantified at 450nm with a reference wavelength of 655nm.
Background binding was subtracted from the value obtained for
binding to the consensus DNA sequence.
Statistical analysis
Statistical analysis was performed by Student’s t-test.
RESULTS
Generation of LNCaP-JIP-1 cells
LNCaP cells were transfected with an expression vector encoding
JBD of JIP-1, and G418-resistant clones #2 and #3 were isolated
that stably expressed JBD, detectable with anti-Flag antibody
(Figure 1A). The level of JIP-1 was higher in clone #2 than #3;
therefore, clone #2 LNCaP-JIP-1 cells were used in further studies
unless indicated.
JIP blocked TPA-induced phosphorylation and expression
of c-Jun as well as AP-1 reporter activity in LNCaP-JIP-1
cells
12-0-tetradecanoylphorbol-13-acetate (10
 9–10
 8moll
 1,1 6 h )
caused phosphorylation of JNK in a dose-dependent manner in
both wild-type and JIP-1-transfected LNCaP cells (Figure 1B). 12-
0-tetradecanoylphorbol-13-acetate also increased expression of c-
Jun and phosphorylated c-Jun in wild-type LNCaP cells, but not in
LNCaP-JIP-1 cells (Figure 1B). To evaluate the influence of
expression of JIP-1 upon AP-1 transcriptional activity, reporter
assays were performed using an AP-1 luciferase construct,
which contained three copies of the TPA response elements
WT #2 #3
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Figure 1 (A) Establishment of JIP-1-expressing LNCaP cells. LNCaP cells
were transfected with an expression vector encoding the JBD of JIP-1, and
G418-resistant clones #2 and #3 were isolated. Proteins were extracted
from these cells, and subjected to Western blot analysis. The membrane
was sequentially probed with antibodies against Flag and b-actin. (B)
Expression of JIP-1 in LNCaP cells inhibits phosphorylation of Ser-63 of c-
Jun and decreases total levels of c-Jun protein. JNK-binding domain of JIP-1
was stably transfected in LNCaP cells. Wild-type LNCaP cells and LNCaP-
JIP-1 cells were cultured either with or without TPA (10
 9,1 0
 8moll
 1)
for 18h, then proteins were extracted and subjected to Western blot
analysis. The membrane was sequentially probed with antibodies against
phospho-JNK (Thr-183 and Tyr-185), JNK-1, phospho-c-Jun (ser-63), c-Jun,
b-Actin and Flag. (C) Expression of JIP-1 inhibits TPA-induced AP-1
reporter activity in LNCaP cells. The reporter construct (TRE-Luc) is shown
at the top. Wild-type or JIP-1 stably expressing LNCaP cells were
transfected with the reporter construct (0.8mg) and cultured either with or
without TPA (10
 9moll
 1) for 6h. pRL-SV40-Luciferase (Renilla lucifer-
ase) vector was cotransfected for normalisation. SDs derived from
duplicate experiments with triplicate dishes per point. *, Po0.005 as
determined by Student’s t-test differences between wild-type and JIP-1
cells.
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s(TRE). 12-0-tetradecanoylphorbol-13-acetate (10
 9moll
 1,6 h )
induced AP-1 reporter activity by 2.7-fold in wild-type LNCaP
cells; however, in LNCaP-JIP-1 cells, induction was 1.3-fold,
compared to untreated LNCaP-JIP-1 cells (Figure 1C). Taken
together, these data suggested that JIP-1 effectively blocked TPA-
induced c-Jun/AP-1 transcriptional activity.
JIP-1 protected LNCaP-JIP-1 cells from growth inhibition
mediated by TPA
Effect of different concentrations of TPA on cellular progression
was measured by several different assays. Growth in liquid culture
was measured by MTT assay (described in Materials and Methods
section). Almost identical MTT activity was obtained from the
untreated control cells of both the wild-type and JIP-1-transfected
LNCaP cells (data not shown). In the presence of increasing
concentrations of TPA, both clone #2 and #3 LNCaP-JIP-1 cells
showed significantly higher MTT activity compared to the wild-
type cells (Figure 2A). For example, TPA (10
 8moll
 1, 4 days)
reduced MTT activity by 75% in the wild-type cells; on the other
hand, under similar conditions, only a 15% reduction occurred in
the clone #2 LNCaP-JIP-1 population (Po0.005). Consistent with
these results, colony assays showed that LNCaP-JIP-1 cells were
more resistant to increasing concentrations of TPA compared to
wild-type cells (Figure 2B). Both wild-type and clone #2 of JIP-1-
transfected cells formed approximately 300 colonies in untreated
control wells, and colony size was almost the same in both groups.
12-0-tetradecanoylphorbol-13-acetate effectively inhibited the clo-
nal growth by 50% (ED50) at approximately 1.3 10
 10moll
 1 for
the wild-type LNCaP cells and 10
 9moll
 1 for clone #2 LNCaP-
JIP-1 cells; this TPA concentration inhibited clonal growth of wild-
type cells by 85% (Po0.01) (Figure 2B).
JNK inhibitor SP600125 protected LNCaP cells from
growth inhibition mediated by TPA
Furthermore, we cultured LNCaP cells in the presence of the JNK
inhibitor SP600125 to block the JNK/c-Jun/AP-1 pathway. As
shown in Figure 3A, exposure of LNCaP cells to SP600125 (10 or
20mM) effectively downregulated levels of TPA-induced phosphor-
ylation of JNK and c-Jun in a dose-dependent manner. Also,
SP600125 completely inhibited TPA-stimulated AP1/DNA-binding
activity in these cells, as measured by an ELISA-based assay
(Figure 3B). LNCaP cells were cultured with either TPA or
SP600125 (20mM) alone or the combination of both for 4 days.
SP600125 alone did not affect the proliferation of LNCaP cells
(Figure 3C); SP600125 blunted the ability of TPA to induce growth
arrest of LNCaP cells as measured by MTT assay (Figure 3C).
JIP attenuated TPA-induced apoptosis and cell cycle arrest
in LNCaP-JIP-1 cells
To detect apoptosis, TUNEL assay was performed. As previous
studies (Koeffler et al, 1981; Kaneki et al, 1999) showed, TPA
(10
 9–10
 7moll
 1, 24h) induced apoptosis in wild-type LNCaP
cells in a dose-dependent manner (Figure 4A). For example, 10
 8
and 10
 7moll
 1 of TPA induced 2077 and 5578% of cells to
become apoptotic, respectively. In contrast, only 572 and 1275%
of LNCaP-JIP-1 cells were apoptotic in the presence of 10
 8 and
10
 7moll
 1 TPA, respectively.
Cell cycle analysis showed that untreated wild-type and JIP-1-
transfected cells were essentially identically in the percent cells in
each phase of the cell cycle (Figure 4B). A difference in these
populations of cells emerged in the presence of the phorbol diester.
12-0-tetradecanoylphorbol-13-acetate (10
 9–10
 8moll
 1,1 6 h )
induced a G2/M cell cycle arrest in the wild-type LNCaP cells in
a dose-dependent manner (control, 1073%; TPA 10
 9moll
 1,
2378%; TPA 10
 8moll
 1,3 9 75%). On the other hand, the
population of LNCaP-JIP-1 cells in G2/M of the cell cycle was
significantly attenuated (control, 974%; TPA, 10
 9moll
 1,
1478% (P¼0.01), 10
 8moll
 1,2 3 79% (P¼0.05)). The appear-
ance of cells with a fractional DNA content (pre-G0/G1 phase), a
feature characteristic of apoptosis, was prominent in wild-type
LNCaP cells after their exposure to TPA with nearly twice the
number of cells accumulating in the pre-G0/G1 phase in wild-type
LNCaP cells treated with 10
 8moll
 1 TPA (wild type, 2873%) as
compared to the JIP-1-transfected cells (1576%).
The cyclin-dependent kinase inhibitor p21
waf1 helps to regulate
the cell cycle; previous studies showed that TPA induced p21
waf1 in
LNCaP cells associated with slowing of the cell cycle (Garzotto et al,
1998). Consistent with the results from the proliferation assays and
cell cycle analysis, induction of p21
waf1 by exposure to TPA was
attenuated by about 60% in the LNCaP-JIP-1 cells compared to
LNCaP cells (Figure 5). The p53 protein is the upstream regulator
of p21
waf1. The TPA-induced elevated levels of p53 were also
blunted in the LNCaP-JIP-1 cells by about half compared to LNCaP
cells (Figure 5).
12-0-tetradecanoylphorbol-13-acetate decreases androgen
responsiveness in LNCaP cells which is independent of the
JNK/c-Jun pathway
We evaluated the responsiveness of prostate cancer cells to
androgen when their JNK/c-Jun pathway was blocked, taking
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Figure 2 Expression of JIP-1 partially rescues LNCaP cells from TPA-
induced growth inhibition. (A) MTT assay: Wild-type or JIP-1 stably
transfected LNCaP cells were placed in 96-well plates and cultured either
with or without TPA (10
 10–10
 8moll
 1). After 4 days, the cells were
treated with MTT for 4h, and MTT activity was measured. (B) Colony
assay: Wild-type or JIP-1 stably transfected LNCaP cells were plated in soft
agar either with or without TPA (10
 10–10
 8moll
 1), and colonies were
enumerated after 14 days of culture. For both series of studies, each point
represents a mean of two independent experiments with triplicate dishes
for each experimental point; bars, s.d. Results are expressed as mean
percentage of either colonies or MTT activity in control plates containing
cells, not exposed to TPA but cultured with the same amount of diluent
(DMSO). The P-value was determined by Student’s t-test differences
between wild-type and JIP-1 cells.
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sadvantage of the LNCaP-JIP-1 cells. To evaluate the expression
level of PSA in LNCaP-JIP-1 cells treated with DHT7TPA (10
 9–
10
 8moll
 1), Western blot analysis was performed (Figure 6). In
both LNCaP and LNCaP-JIP-1 cell lines, DHT (10
 8moll
 1,1 8h )
markedly and equally induced the expression of PSA. In wild-type
LNCaP cells, TPA (10
 9moll
 1) completely blocked the DHT-
induced expression of PSA without any significant decrease in the
cellular level of AR at this dose, which was consistent with previous
results (Andrews et al, 1992; Sato et al, 1997). Even though LNCaP-
JIP-1 cells were incapable of a TPA-inducible activation of c-Jun
(or phosphorylated c-Jun) (Figure 1B), expression of PSA was
completely abrogated similar to what occurred in the wild-type
cells (Figure 6).
Also, ARE-luciferase reporter assays were performed. The
LNCaP-JIP-1 cells were cultured with DHT (10
 8moll
 1) after
they were transfected with an ARE-E4-luciferase reporter vector in
which ARE I from the PSA gene was concatmerised (Huang et al,
1999; Hisatake et al, 2000). The reporter activity increased about
300-fold after addition of DHT (10
 8moll
 1) as compared with
nontreated control LNCaP and LNCaP-JIP-1 cells. When both cell
types were cultured with the combination of DHT (10
 8moll
 1)
and 10
 9moll
 1 of TPA, luciferase activity was reduced drama-
tically, compared with DHT containing cultures alone (Figure 7).
Thus, the DHT-stimulated upregulation and TPA-induced down-
regulation of ARE reporter activity in wild-type and LNCaP-JIP-1
cells were nearly identical.
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Figure 3 (A) SP600125 inhibits TPA-induced phosphorylation of JNK
and c-Jun in LNCaP cells. LNCaP cells were cultured with TPA
(10
 8moll
 1) either alone or in combination with SP600125 (10 or
20mM) for 16h, then proteins were extracted and subjected to Western
blot analysis. The membrane was sequentially probed with antibodies
against phospho-JNK (Thr-183 and Tyr-185), JNK-1, phospho-c-Jun (ser-
63), and c-Jun. Control cells were cultured in the presence of control
diluent. SP, SP600125. (B) SP600125 inhibits TPA-induced AP-1/DNA
binding activity in LNCaP cells. LNCaP cells were cultured with TPA
(10
 8moll
 1) either alone or in combination with SP600125 (20mM) for
16h, then nuclear proteins were extracted and subjected to ELISA to
measure DNA-binding activity of AP-1. Control cells were cultured in the
presence of control diluent. (C) Exposure of LNCaP cells to JNK inhibitor
SP600125 partially rescues LNCaP cells from TPA-induced growth
inhibition. LNCaP cells were plated in 96-well plates and cultured with
TPA (10
 9 or 10
 8moll
 1), SP600125 (20mM) either alone or in
combination of both. After 4 days, the cells were treated with MTT for
4h, and MTT activity was measured.
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Figure 4 Expression of JIP-1 in LNCaP cells attenuates TPA-induced
apoptosis and cell cycle arrest. (A) TUNEL assay: Wild-type or JIP-1 stably
transfected LNCaP cells were plated in 96-well plates and cultured either
with or without TPA (10
 9–10
 7moll
 1); and 24h later, apoptosis was
determined by TUNEL assay. Results represent the mean7s.d. of two
experiments carried out in triplicates. (B) Cell cycle analysis: Wild-type or
JIP-1 stably transfected LNCaP cells were plated in 12-well plates and
cultured either with or without TPA (10
 9–10
 8moll
 1) for 24h at which
time the cell cycle status was analysed. The P-values were determined by
Student’s t-test difference between wild-type and JIP-1 cells.
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sDISCUSSION
In this study, we showed that growth control of prostate cancer
cells can be mediated through the JNK/c-Jun pathway, but
androgen-responsiveness of these cells can be independent of this
pathway. We established LNCaP cells stably transfected with JBD
of JIP-1 (LNCaP-JIP-1 cells). When LNCaP-JIP-1 cells were
cultured in the presence of TPA, the ability of JNK to
phosphorylate c-Jun was effectively blocked. TPA-induced AP-1
transcriptional activity was abrogated, and TPA-induced growth
arrest and apoptosis were attenuated. Further studies using the
JNK inhibitor SP600125 confirmed the importance of the JNK/c-
Jun/AP-1 signal pathway in TPA-induced growth arrest of LNCaP
cells; SP600125 protected LNCaP cells from TPA-induced growth
arrest. Recently, other investigators also reported the contribution
of the JNK/c-Jun signaling to TPA-mediated apoptosis of LNCaP
cells (Engedal et al, 2002); they transiently transfected JBD of JIP-1
in LNCaP cells to inhibit the JNK/c-Jun signal pathway. These
transiently transfected cells were relatively resistant to TPA-
induced apoptosis compared to untransfected control cells.
JIP-1 significantly attenuated the TPA-induced growth
arrest and apoptosis in LNCaP cells; however, this effect was
partial, indicating that other signal pathways must exist by which
TPA causes decreased growth and increased apoptosis. One
possible candidate is the Ras/Raf/ERK signal pathway. ERK is
another member of the MAPK family which has an important
role in regulating cellular proliferation and differentiation, induced
by growth factors, cytokines, and TPA (He et al, 1999; Wang
et al, 2000). TPA induced phosphorylation of ERK in LNCaP
cells (Gschwend et al, 2000). In agreement with the previous study,
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Figure 5 Expression of JIP-1 in LNCaP cells attenuates their TPA-
induced expression of p53 and p21
waf1. Wild-type and JIP-1 stably
transfected cells were seeded on 60mm plates and incubated until 60–
80% confluency; the medium was replaced with RPMI 1640 containing 10%
FBS either with or without TPA (10
 9–10
 8moll
 1). After 18h, cells
were harvested. Lysates were made and subjected to Western blot
analysis. The band intensities were measured by densitometry.
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Figure 6 Blockade of c-Jun pathway does not prevent decrease levels of
PSA by TPA. Wild-type and JIP-1 stably transfected LNCaP cells at 60%
confluency were incubated in culture medium containing 10% charcoal-
striped FBS for 24h before the addition of DHT (10
 8moll
 1) either with
or without TPA (10
 9–10
 8moll
 1). Cells were cultured for an additional
18h. Lysates were made and subjected to Western blotted. Control: cell
lysates harvested before the addition of reagents. PSA, prostate-specific
antigen; AR, androgen receptor.
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Figure 7 Blockade of Jun pathway does not prevent decrease ARE
activation by TPA in LNCaP cells. Shown at the top is the reporter gene
(ARE4-E4Lux) containing the four concatmerised androgen receptor
response elements (ARE) identical to those in the PSA enhancer, which
is attached to the luciferase (Luc) reporter. Wild-type and JIP-1 stably
transfected LNCaP cells were transfected with ARE4-E4Lux (0.8mg). DHT
(10
 8moll
 1) was added either with or without TPA (10
 9moll
 1).
Results represent the mean7s.d. of three experiments with triplicate
dishes per experimental point. pRL-SV40-Luciferase (renilla luciferase)
vector was cotransfected for normalisation.
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swe have found that TPA-exposure resulted in a slight phosphor-
ylation of ERK in wild type LNCaP cells and a 3-fold
phosphorylation of ERK in LNCaP-JIP-1 cells as measured by
Western blot analysis (data not shown). ERK might function to
compensate for the impaired JNK/c-Jun/AP-1 signal pathway in
LNCaP-JIP-1 cells.
Previous studies showed that cross-talk existed between the
nuclear hormone receptors and c-Jun/AP-1 (Jonat et al, 1990;
Schule et al, 1990; Yang-Yen et al, 1990). c-Jun/AP-1 down-
regulated the glucocorticoid receptor (GCR) activity by inhibiting
the binding of GCR to the GCR response element. AR belongs to
the nuclear hormone receptor family, and regulates target genes
after activation of the receptor by binding of its ligand (Huang et al,
1999; Hisatake et al, 2000). TPA down-regulates AR transcriptional
activity without decreasing levels of AR. Another study suggested
that c-Jun played a role in this inhibition by binding to the DNA-
binding domain of AR, resulting in the inhibition of binding of
activated AR to its AREs (Sato et al, 1997). In our study, AR
mediated transcriptional activity in LNCaP-JIP-1 cells was
disrupted by TPA (10
 9 M), even though phosphorylation and
up-regulation of c-Jun levels and AP-1 reporter activity were
effectively blocked in these cells, suggesting that other pathway(s)
must play a role in the TPA-induced down-regulation of AR signal
activity. As prostate cancer progresses, it often becomes indepen-
dent of androgen control. Our study suggests that this may occur
independent of the JNK/c-Jun pathway. The phosphoinositide 3-
kinase (PI3K)/Akt pathway is constitutively active in LNCaP cells
because of the loss of PTEN expression, and PI3K/AKT was
shown to activate the AR signaling (Wu et al, 1998; Li et al,
2001). TPA might down-regulate PSA by inhibiting the PI3K/AKT
signal pathway. The regulation of gene transcription by nuclear
receptors requires the recruitment of a number of proteins
characterized as coregulators, functioning either as co-activators
or co-repressors (Glass and Rosenfeld, 2000; Rosenfeld and Glass,
2001). Further studies will explore if TPA could inhibit
the recruitment of co-activators or promote the recruitment of
co-repressors of AR.
Taken together, these studies provide evidence that JNK helps to
mediate the TPA-induced cell growth arrest and apoptosis in
LNCaP human prostate cancer cells; and this effect might be
mediated via phosphorylation of c-Jun. In contrast, we showed that
the TPA-induced down-regulation of AR transcriptional activity
was independent of the JNK/c-Jun/AP-1 signal pathway (Figure 8).
A recent phase I clinical study in individuals with relapsed/
refractory hematological malignancies demonstrated the feasibility
of TPA administration to humans resulting in therapeutic
responses (Strair et al, 2002). Also, bryostatin 1, a related
compound, has shown clinical activity when combined with high
dose 1-beta-D-arabinofuranosylcytosine in individuals with re-
lapsed/refractory acute leukemia (Cragg et al, 2002). Additional
clinical studies in individuals with prostate cancer should be
considered.
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